Linkage between Polymorphisms in the prostate specific antigen AREI gene region, prostate cancer risk, and circulating tumor cells

被引:54
作者
Medeiros, R
Morais, A
Vasconcelos, A
Costa, S
Pinto, D
Oliveira, J
Carvalho, R
Lopes, C
机构
[1] PISO, Edificio Labs, Inst Portugues Oncol, Unit Mol Oncol, P-4200072 Oporto, Portugal
[2] Inst Portugues Oncol Francisco Gentil, Dept Urol, Oporto, Portugal
关键词
prostate-specific antigen; polymorphism; prostate cancer; micrometastasis; genotyping; PCR; cancer risk;
D O I
10.1002/pros.10135
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND. The prostate specific antigen (PSA) gene has a polymorphic androgen response element (ARE) sequence with two alleles, A and G. PSA A-allele carriers have higher serum PSA levels in healthy men (HM). METHODS. We analysed DNA samples from 278 (556 alleles) unrelated individuals, 127 HM and 151 prostate cancer (PC) patients, for PSA ARE1 genotypes. RESULTS. The analysis of the frequencies from the 556 alleles indicates a significant over-representation of A-allele in the PC group under the age of 67 compared with the HM group (63.3% vs. 48.8%; P = 0.009). We found that men carrying two A-alleles have increased risk for PC onset under the age of 67 (odds ratio [OR] = 2.92; 95% confidence interval [CI], 1.10-7.86; P = 0.013). Multivariate logistic regression analysis confirmed this association (OR = 1.82; 95% CI, 1.03-3.22; P = 0.037). Furthermore, the homozygosity for the A-allele was associated with higher serum PSA levels (P = 0.027) and with the presence of circulating tumor cells in the blood of PC patients (P = 0.018). CONCLUSION. Our results indicate that polymorphism in the PSA gene promoter may be an important biomarker for prostate cancer risk, especially for an earlier onset of PC. (C) 2002 Wiley-Liss, Inc.
引用
收藏
页码:88 / 94
页数:7
相关论文
共 27 条
[1]  
ARMBRUSTER DA, 1993, CLIN CHEM, V39, P181
[2]   SINGLE-STEP METHOD OF RNA ISOLATION BY ACID GUANIDINIUM THIOCYANATE PHENOL CHLOROFORM EXTRACTION [J].
CHOMCZYNSKI, P ;
SACCHI, N .
ANALYTICAL BIOCHEMISTRY, 1987, 162 (01) :156-159
[3]   PREDICTING RADIONUCLIDE BONE-SCAN FINDINGS IN PATIENTS WITH NEWLY DIAGNOSED, UNTREATED PROSTATE-CANCER - PROSTATE SPECIFIC ANTIGEN IS SUPERIOR TO ALL OTHER CLINICAL-PARAMETERS [J].
CHYBOWSKI, FM ;
KELLER, JJL ;
BERGSTRALH, EJ ;
OESTERLING, JE .
JOURNAL OF UROLOGY, 1991, 145 (02) :313-318
[4]   An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter [J].
Cleutjens, KBJM ;
vanderKorput, HAGM ;
vanEekelen, CCEM ;
vanRooij, HCJ ;
Faber, PW ;
Trapman, J .
MOLECULAR ENDOCRINOLOGY, 1997, 11 (02) :148-161
[5]  
ESTEVE J, 1993, FACTS FIGURES CANC E, P1
[6]   CLINICAL AND MOLECULAR TECHNIQUES FOR DIAGNOSIS AND MONITORING OF PROSTATIC-CANCER [J].
FOSTER, CS ;
ABEL, PD .
HUMAN PATHOLOGY, 1992, 23 (04) :395-401
[7]  
Gala JL, 1998, CLIN CHEM, V44, P472
[8]   Review: Polymerase chain reaction detection of micrometastases and circulating tumor cells: Application to melanoma, prostate, and thyroid carcinomas [J].
Ghossein, RA ;
Carusone, L ;
Bhattacharya, S .
DIAGNOSTIC MOLECULAR PATHOLOGY, 1999, 8 (04) :165-175
[9]   EVALUATION OF PAP AND PSA GENE-EXPRESSION IN PROSTATIC HYPERPLASIA AND PROSTATIC-CARCINOMA USING NORTHERN-BLOT ANALYSES, IN-SITU HYBRIDIZATION AND IMMUNOHISTOCHEMICAL STAININGS WITH MONOCLONAL AND BISPECIFIC ANTIBODIES [J].
HAKALAHTI, L ;
VIHKO, P ;
HENTTU, P ;
AUTIOHARMAINEN, H ;
SOINI, Y ;
VIHKO, R .
INTERNATIONAL JOURNAL OF CANCER, 1993, 55 (04) :590-597
[10]   CIRCULATING PROSTATE SPECIFIC ANTIGEN-POSITIVE CELLS CORRELATE WITH METASTATIC PROSTATE-CANCER [J].
HAMDY, FC ;
LAWRY, J ;
ANDERSON, JB ;
PARSONS, MA ;
REES, RC ;
WILLIAMS, JL .
BRITISH JOURNAL OF UROLOGY, 1992, 69 (04) :392-396